TW202039507A - 使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法 - Google Patents

使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法 Download PDF

Info

Publication number
TW202039507A
TW202039507A TW109106773A TW109106773A TW202039507A TW 202039507 A TW202039507 A TW 202039507A TW 109106773 A TW109106773 A TW 109106773A TW 109106773 A TW109106773 A TW 109106773A TW 202039507 A TW202039507 A TW 202039507A
Authority
TW
Taiwan
Prior art keywords
salt
pembrolizumab
cancer
compound
day
Prior art date
Application number
TW109106773A
Other languages
English (en)
Chinese (zh)
Inventor
米倉和比古
平井洋
松岡和明
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202039507A publication Critical patent/TW202039507A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109106773A 2019-02-28 2020-03-02 使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法 TW202039507A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2019-035603 2019-02-28
JP2019035603 2019-02-28
JP2019112619 2019-06-18
JP2019-112619 2019-06-18

Publications (1)

Publication Number Publication Date
TW202039507A true TW202039507A (zh) 2020-11-01

Family

ID=72239799

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109106773A TW202039507A (zh) 2019-02-28 2020-03-02 使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法
TW109106772A TW202045182A (zh) 2019-02-28 2020-03-02 使用3,5-二取代苯炔基化合物與免疫檢查點抑制劑之癌症治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109106772A TW202045182A (zh) 2019-02-28 2020-03-02 使用3,5-二取代苯炔基化合物與免疫檢查點抑制劑之癌症治療法

Country Status (8)

Country Link
US (2) US20220184082A1 (https=)
EP (2) EP3932425A4 (https=)
JP (6) JPWO2020175697A1 (https=)
KR (2) KR20210130774A (https=)
AU (4) AU2020228514B2 (https=)
MA (2) MA55088A (https=)
TW (2) TW202039507A (https=)
WO (2) WO2020175704A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
AU2020352668A1 (en) * 2019-09-26 2022-03-31 Janssen Pharmaceutica Nv Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (en) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
DK2657233T3 (da) * 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS

Also Published As

Publication number Publication date
WO2020175697A1 (ja) 2020-09-03
EP3932425A1 (en) 2022-01-05
EP3932427A1 (en) 2022-01-05
US20220125793A1 (en) 2022-04-28
AU2020228514A1 (en) 2021-10-07
MA55088A (fr) 2022-01-05
KR20210130774A (ko) 2021-11-01
JP2025075059A (ja) 2025-05-14
KR20210131387A (ko) 2021-11-02
WO2020175704A1 (ja) 2020-09-03
US20220184082A1 (en) 2022-06-16
JP2023112136A (ja) 2023-08-10
JP2024152860A (ja) 2024-10-25
JPWO2020175704A1 (https=) 2020-09-03
MA55091A (fr) 2022-01-05
TW202045182A (zh) 2020-12-16
EP3932427A4 (en) 2022-12-07
EP3932425A4 (en) 2022-12-07
AU2020228514B2 (en) 2025-02-27
AU2020229714B2 (en) 2025-02-27
JPWO2020175697A1 (https=) 2020-09-03
JP2023096156A (ja) 2023-07-06
AU2020229714A1 (en) 2021-10-07
AU2025203861A1 (en) 2025-06-19
AU2025203865A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
TW202039507A (zh) 使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法
JP2020517640A5 (https=)
TWI747868B (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
IL305621A (en) Methods for training patients for T-cell therapy
TW201545759A (zh) 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
JP2023165946A (ja) Ｅｐ４阻害剤およびその使用
JP2020517629A5 (https=)
US20220160718A1 (en) Compositions and methods of treating cancer
Fan et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and combination rationales
EP3646869B1 (en) Chemotherapy for cancer using azabicyclo compound
Ameri et al. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer
RU2822064C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
RU2843836C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и ингибитора иммунной контрольной точки
TW202517295A (zh) 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法
TW202515539A (zh) 使用伏替巴替尼（ｆｕｔｉｂａｔｉｎｉｂ）及派姆單抗（ｐｅｍｂｒｏｌｉｚｕｍａｂ）治療癌症之方法